The results of COMP004 build upon previous findings from the Phase 2b trial COMP001, which showed that a single 25mg dose of COMP360 psilocybin was associated with a rapid and highly statistically ...

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms ...

CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, 2025, 8:00 a.m. ET ...

In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic ...

LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ladies and gentleman thank you for standing by, and welcome to the COMPASS Pathways' Ltd. Fourth Quarter 2024 Investor Call. [Operator Instructions] I would now hand today’s call over to Steve ...